Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylprednisolone aceponate cream versus Advantan and vehicle in mild to moderate atopic dermatitis
2022-002644-48Phase 3
- Sponsor
- Dermapharm
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of methylprednisolone aceponate and vehicle in atopic dermatitis (AD) (3 arms), sponsored by Dermapharm. Primary endpoint: Percent change in EASI score from baseline to end of treatment.
02
Drugs
methylprednisolone aceponatevehicle
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2022-002644-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002644-48.